首页> 外文期刊>Bone marrow transplantation >Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.
【24h】

Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.

机译:在老年CML患者中使用TBI(8 Gy),氟达拉滨,环磷酰胺和ATG进行强度降低的调理可提供出色的结果,尤其是在疾病早期进行时。

获取原文
获取原文并翻译 | 示例
           

摘要

Allogeneic bone marrow or stem cell transplantation is a curative therapeutic option for chronic myelogenous leukemia. In order to decrease the toxicity of the procedure, the dosage of total body irradiation was reduced from 12 to 8 Gy and subsequently the dose of cyclophosphamide from 120 to 80 mg/kg. The purine analogue fludarabine, ATG, cyclosporine A and a short course of methotrexate were given for immune suppression. So far, 35 elderly CML patients with sibling and unrelated donors have been transplanted. Transplant-related mortality at day + 100 was 11%. After engraftment, all patients achieved a complete cytogenetic remission. Relapse occurred in 14% of the patients. The risk of relapse was significantly higher in those patients transplanted in second chronic or accelerated phase (P = 0.048). After a median follow-up of 30 months (range 12-62), 63% of the patients are alive. Those patients transplanted within the first year from diagnosis had an overall survival of 79% (P = 0.049), emphasizing the benefit of early transplantation. Stepwise reduction of conditioning intensity resulted in stable engraftment, low relapse rates and encouraging overall survival in this high-risk patient group.
机译:同种异体骨髓或干细胞移植是治疗慢性粒细胞性白血病的一种治疗选择。为了降低该方法的毒性,将全身照射的剂量从12 Gy减少到8 Gy,随后将环磷酰胺的剂量从120 mg / kg减少到80 mg / kg。给予嘌呤类似物氟达拉滨,ATG,环孢菌素A和短疗程的甲氨蝶呤用于免疫抑制。到目前为止,已经移植了35例具有同胞和无关亲属的老年CML患者。第100天时与移植相关的死亡率为11%。植入后,所有患者均实现了完全的细胞遗传学缓解。 14%的患者发生复发。在第二个慢性或加速期移植的患者中,复发的风险明显更高(P = 0.048)。在平均随访30个月(范围12-62)后,有63%的患者还活着。从诊断开始的第一年内移植的患者总生存率为79%(P = 0.049),强调了早期移植的益处。在此高危患者组中,调理强度的逐步降低可导致稳定的植入,低复发率并促进总体生存。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号